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Abstract: 
The amplification inherent in transcription and translation of DNA has already been exploited for 
the development of highly sensitive immunoassays by using a reporter gene as a label that, upon 
in vitro expression, generates multiple enzyme molecules in solution (expression immunoassay). 
The most challenging task in the development of an expression immunoassay is to link the 
antibody to a reporter gene that also contains control elements for transcription/translation. In 
this work, we prepare heterobifunctional linkers that consist of a modified avidin or streptavidin 
covalently attached to an oligonucleotide (dA)40. (Strept)avidin interacts with a biotinylated 
detection antibody whereas the oligonucleotide hybridizes with a complementary poly(dT) tail 
added enzymically to the 3′ end of the reporter gene. The linker is evaluated in a model two-site 
(sandwich-type) immunoassay performed in microtiter wells. A 4.3 kb plasmid containing the 
firefly luciferase cDNA is used as a reporter. 
 




A reporter gene is a DNA fragment coding for a protein that can be readily detected at low 
concentrations. Most widely used reporter genes encode enzymes (e.g. chloramphenicol acetyl 
transferase, alkaline phosphatase, luciferase, etc.), fluorescent proteins (GFP) and photoproteins 
(aequorin). Analytical applications of reporter genes include [1], (i) the spatial and temporal 
monitoring of gene expression in vivo[2] and [3], (ii) the investigation of the strength and 
developmental regulation of promoters/enhancers fused to the reporter gene [2] and [3], (iii) the 
construction of light-emitting biosensors based on whole cells transfected with a reporter gene 
that is fused to an inducible promoter [1] and [4], and (iv) the development of in vitro 
immunoassays and hybridization assays for determination of antigens and nucleic 
acids [5], [6],[7] and [8]. 
Expression immunoassay uses a reporter gene as a label [5], [6] and [7]. Following completion 
of the immunoreaction, the reporter gene undergoes an in vitro (cell-free), coupled transcription 
and translation to generate multiple active enzyme molecules per immunocomplex. Therefore, 
gene expression provides another significant amplification step in addition to substrate turnover, 
thereby improving greatly the detectability of the assay. All reagents required for gene 
expression are added as a mixture in a single step. It has been shown [5], [6] and [7] that, 
although the transcription and translation process consists of a series of reactions that require the 
concerted action of several factors, the final outcome is a reproducible, linear relationship 
between the amount of input DNA and the activity of the synthesized enzyme. 
Currently, the most challenging task in the development of an expression immunoassay is to link 
the antibody to the reporter gene (or the entire vector), which is a several kilobase long double-
stranded DNA fragment that also contains control elements for transcription and translation. A 
functional macromolecular complex between antibody and reporter gene should retain both the 
binding affinity for the antigen and the expressibility of the DNA fragment. In previous 
reports [5] and [7], a streptavidin–reporter gene complex was prepared by using a series of 
tedious and time-consuming steps. A plasmid was first linearized followed by a fill-in reaction 
using Klenow DNA polymerase and biotin-dNTP to produce fragments that were biotinylated at 
both 3′ termini. There are four binding sites on each (strept)avidin molecule [9]. In order to 
avoid cyclization and polymerization of biotinylated DNA fragments during complexation, one 
of the DNA termini was first removed by digestion. The digested fragments were separated by 
gel electrophoresis, and the fragment containing the reporter gene was purified directly from the 
gel. The complexation was carried out with an excess of streptavidin and the complexes were 
purified by size-exclusion HPLC. The overall yield was 10–20% due to the multiple purification 
steps involved. The difficulty in preparing the complex constitutes the main obstacle for the 
wider use of gene expression as a highly sensitive amplification system in immunoassays. 
The objective of the present work was to eliminate all the above difficulties by preparing a 
heterobifunctional linker between antibody and reporter gene. It consists of (strept)avidin 
covalently attached to an oligonucleotide (dA)40. The linker is universal because (strept)avidin 
interacts with any biotinylated antibody or any biotinylated binder in general, such as peptides or 
receptors. The oligonucleotide (dA)40 hybridizes with a complementary poly(dT) tail added 
enzymically to any reporter gene. Both biotinylation of binders and tailing of DNA are reactions 
performed readily without interfering with the respective biological activity. The linker is 
applied to a model sandwich-type immunoassay for prostate specific antigen (PSA) using a 
4.3 kb plasmid containing the firefly luciferase cDNA as a reporter. 
2. Experimental 
2.1. Instrumentation 
Immunoasssays were performed in microtiter wells using the Amerlite shaker/incubator 
(Amersham, Oakville, Ont., Canada). The microtiter plate washer, model EAW II, was from 
SLT-Lab Instruments, (Salzburg, Austria). Luminescence measurements were carried out using a 
liquid scintillation counter (model LS-6500, Beckman Instruments Inc., Fullerton, CA) in the 
single-photon monitoring mode. 
2.2. Materials 
Bgl I was obtained from New England Biolabs (Beverly, MA). Terminal deoxynucleotidyl 
transferase, streptavidin (SA), bovine serum albumin (BSA), and blocking reagent (cat. 
#1096176) were purchased from Boehringer Mannheim Corporation (Indianapolis, IN). N-
Succinimidyl-S-acetylthioacetate (SATA), sulfo-N-hydroxysuccinimide ester of biotin (sulfo-
NHS-LC-biotin), sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate 
(SMCC) and maleimide-activated neutravidin were from Pierce (Rockford, IL). T7 RNA 
polymerase, deoxyribonucleotides (dNTPs, 100 mmol/l solutions), NAP columns were from 
Amersham Pharmacia Biotech (Piscataway, NJ). Centricon-30 concentrators were from Amicon 
Inc. (Beverly, MA). Solutions of various concentrations of PSA were prepared by diluting PSA 
(Scripps Laboratories, CA) in 50 mmol/l Tris, pH 7.8, 60 g/l BSA, and stored at 4 °C. 
Monoclonal capture (cat. #8301) and detection (cat. #8311) anti-PSA antibodies were obtained 
from Diagnostic Systems Laboratories (Webster, TX) [10]. Linear DNA markers (lambda-DNA 
digested with Eco RI and Hind III and containing fragments from 1.2 to 21.2 kbp), EDTA, 
ethidium bromide, coenzyme A, tricine, and hydroxylamine hydrochloride were from Sigma (St. 
Louis, MO). U-bottom, transparent, polystyrene microtiter wells (Nunc, Maxisorp) were 
obtained from Life Technologies (Burlington, Ont., Canada). The TNT T7 rabbit reticulocyte 
lysate, used for the in vitro transcription–translation reactions, and beetle luciferin are available 
from Promega Corp. (Madison, WI). 
The oligodeoxynucleotides (dA)40 and a 17mer (5′-GTAGGCCTCAGCTGGAA-3′), both 
modified with a primary amino group at the 5′ end, were synthesized by Oligos Etc Inc. 
(Wilsonville, OR). 
The wash solution consisted of 50 mmol/l Tris, pH 7.4, 150 mmol/l NaCl, and 1 ml/l Tween-20. 
The assay buffer contained 50 mmol/l Tris, pH 7.8, 60 g/l BSA, 0.5 mmol/l KCl, 0.5 g/l NaN3, 
and 0.5 g/l Triton X-100. The conjugation buffer contained 0.1 mol/l sodium phosphate, pH 7.0, 
and 5 mmol/l EDTA. The blocking solution consisted of 10 g/l blocking reagent, 100 mmol/l 
maleic acid, and 150 mmol/l NaCl, pH 7.5. The hybridization buffer contained 60 mmol/l 
sodium citrate, 0.6 mol/l NaCl and 10 g/l blocking reagent. The firefly luciferase substrate 
solution contained 20 mmol/l tricine, pH 7.8, 1.1 mmol/l magnesium carbonate pentahydrate, 
2.7 mmol/l MgSO4, 0.1 mmol/l EDTA, 33 mmol/l dithiothreitol, 270 μmol/l coenzyme A, 
530 μmol/l ATP, and 470 μmol/l luciferin [11]. 
2.3. Preparation of poly(dT)-tailed DNA encoding firefly luciferase (poly(dT)-Luc DNA) 
A DNA plasmid (4.3 kbp Luc DNA) containing the T7 RNA polymerase promoter upstream 
from the firefly luciferase gene, was linearized as follows: 100 μg of the plasmid were mixed 
with 200 units of Bgl I in 325 μl of 50 mmol/l Tris–HCl, pH 7.9, 100 mmol/l NaCl, 10 mmol/l 
MgCl2, 1 mmol/l dithiothreitol. The reaction mixture was incubated at 37 °C for 2 h. The 
linearized DNA fragment was purified by ethanol precipitation. The 3′ ends of the purified 
DNA were subsequently tailed with dTTP by using terminal deoxynucleotidyl transferase. The 
reaction mixture (20 μl) consisted of 10 μg of Luc DNA, 700 pmol dTTP, 25 units of terminal 
transferase, 25 mmol/l Tris–HCl, pH 6.6, 200 mmol/l potassium cacodylate, 5 mmol/l CoCl2, and 
250 mg/l BSA. The mixture was incubated at 37 °C for 60 min, and the reaction was terminated 
by adding 2 μl of 2 mmol/l EDTA. The tailed DNA fragment was used without purification. 
2.4. Biotinylation of anti-PSA antibody 
The monoclonal anti-PSA antibody (0.2 mg) was dialyzed overnight against 3.5 l of 0.1 mol/l 
sodium bicarbonate at 4 °C. The antibody was then diluted with 0.5 mol/l carbonate buffer, pH 
9.1, to a final concentration of 0.5 g/l. For biotinylation, 1 mg of sulfo-NHS-LC-biotin was 
dissolved in 50 μl dimethyl sulfoxide and 12.5 μl (0.25 mg) aliquot was added to the antibody 
solution. The mixture was incubated for 2 h at room temperature. The biotinylated antibody was 
stored at 4 °C and used without purification. 
2.5. Preparation of the heterobifunctional linkers 
The 5′ amino group of (dA)40 was first derivatized with SATA in a 40 μl reaction mixture 
containing 2.5 nmol of (dA)40, 250 nmol of SATA, and 0.1 mol/l carbonate buffer, pH 9.1. 
SATA was added to the mixture as a 20 mmol/l freshly prepared solution in 0.1 mol/l carbonate 
and 50% dimethylformamide. The mixture was incubated at room temperature for 60 min. The 
derivatized (dA)40 was purified from excess SATA by size-exclusion chromatography using a 
NAP column with an elution buffer containing 10 mmol/l ammonium carbonate, pH 6.8. The 
(dA)40 solution was lyophilized to dryness and then reconstituted in conjugation buffer. The 
SATA-derivatized (dA)40 (2.5 nmol) was mixed with 0.25 nmol of maleimide-activated avidin in 
the conjugation buffer (total volume 50 μl) and the reaction was initiated by deacetylation with 
hydroxylamine (final concentration 0.1 mol/l) to deprotect the sulfhydryl group. The reaction 
was allowed to proceed for 60 min at room temperature. Afterwards, the volume was increased 
to 2 ml with 0.1 mol/l sodium phosphate (pH 7.0) and the free oligo was removed by 
ultrafiltration using Centricon-30. The purification step was repeated twice. The linker was 
stored at −20 °C. 
A streptavidin-(dA)40 linker was prepared as follows: streptavidin (0.96 nmol) was first 
derivatized with 38 nmol SMCC in 0.1 mol/l phosphate buffer, pH 7.0 (24 μl reaction mixture). 
After a 60 min incubation at room temperature, the free SMCC was removed by ultrafiltration 
using Centricon-30. The derivatized streptavidin was conjugated to the SATA-derivatized 
(dA)40 as described above for avidin. 
2.6. Application of the heterobifunctional linker to a sandwich-type immunoassay 
Microtiter wells were coated overnight at room temperature with 25 μl of 5 mg/l capture anti-
PSA antibody, diluted in 50 mmol/l Tris, pH 7.8, and 0.5 g/l NaN3. Before use, the wells were 
washed six times with wash solution. A 5 μl aliquot of PSA standard (or diluted serum sample), 
and 20 μl of 0.5 mg/l biotinylated anti-PSA antibody, diluted in assay buffer, were added into 
each well. The immunoreaction was allowed to proceed for 60 min with continuous shaking. At 
the end of the incubation, any unbound biotinylated anti-PSA was removed by washing the wells 
as above. Afterwards, 25 μl of 8 nmol/l linker (diluted in blocking solution), was added into 
each well and incubated for 15 min followed by washing. Subsequently, 25 μl of 1.6 nmol/l 
poly(dT)-Luc DNA, diluted in hybridization buffer, were added into each well and incubated for 
15 min. The wells were then washed eight times with wash solution and two times with 
50 mmol/l potassium acetate. The bound firefly luciferase-coding DNA was expressed into 
active luciferase molecules by an in vitro coupled (one-step) transcription–translation reaction. 
The 25 μl of transcription–translation mixture was added into each well and incubated at 30 °
C for 90 min. The activity of synthesized luciferase was measured by mixing 2 μl of the 
transcription–translation reaction product with 50 μl of luciferase substrate solution (at room 
temperature) and monitoring the emitted luminescence for 1 min using the liquid scintillation 
counter. 
2.7. Analysis of clinical specimens 
Serum samples were diluted 10-fold in blocking solution prior to the analysis. The PSA 
concentration of the serum samples was determined by using a calibration curve constructed 
from PSA standards, whose concentrations were confirmed by the Abbott IMx PSA assay 
(Abbott Laboratories, IL). 
3. Results and discussion 
The series of chemical reactions that are involved in the preparation of the heterobifunctional 
linker is summarized in Fig. 1. In the first step, the N-hydroxy succinimide ester functional group 
of SATA reacts with the primary amino group at the 5′ end of (dA)40 to produce a protected 
sulfhydryl derivative. The acetyl protecting group is then removed by a treatment with 
hydroxylamine and the released SH group reacts with maleimide groups on (strept)avidin 
which were introduced by treatment with SMCC. Fig. 1 also presents the configuration of a 
microtiter well-based sandwich-type immunoassay using the (strept)avidin-(dA)40conjugate as a 
heterobifunctional linker between a biotinylated detection antibody and an enzyme-coding 
reporter gene. 
 
Fig. 1. Upper panel: a schematic diagram of the series of reactions involved in the preparation of 
the heterobifunctional linker. 5′ Amino-modified oligonucleotide (dA)40 is first derivatized with 
SATA to give an acetylated sulfhydryl group that, in turn, is deprotected with hydroxylamine, 
and conjugated to maleimide-activated avidin or streptavidin. Lower panel: sandwich-type 
immunoassay configuration using the heterobifunctional linker between the detection antibody 
and a reporter gene. After completion of the immunoreaction, the reporter gene is subjected to 
one-step in vitro transcription/translation and the activity of synthesized enzyme is monitored. B: 
biotin; Av: avidin. 
For (strept)avidin-(dA)40 conjugate to be suitable as a linker between an antibody and a reporter 
gene, the following requirements must be fulfilled; (a) (strept)avidin retains its affinity for biotin 
after conjugation, (b) the conjugation does not interfere with the hybridization of (dA)40 to the 
poly(dT)-tailed reporter gene, (c) the bound reporter gene is accessible for in vitro transcription 
and translation and (d) the non-specific binding of the linker and the reporter gene to the solid 
phase used in the assay is low. 
A modified avidin (neutravidin) was chosen in this study because it has a significantly lower 
isoelectric point (pI=6.3). As a consequence, its non-specific binding to the solid phase is 
relatively low. 
The SATA to (dA)40 molar ratio required for complete derivatization was studied in the range of 
20–400. The SATA-derivatized (dA)40 was conjugated to avidin and the linker was used in the 
immunoassay as described in Section 2. The highest signal was obtained with molar ratios 
greater than 100. The signal dropped by 60% when the ratio decreased to 20 because of the 
incomplete derivatization of the oligonucleotide. 
The SATA-derivatized (dA)40 to maleimide-activated avidin molar ratio was studied in the range 
of 2–50 (Fig. 2). Initially the signal increases when the SATA-(dA)40 to avidin ratio is increased 
because the fraction of avidin molecules that are conjugated to (dA)40 increases. The maximum 
signal is obtained at a ratio of 10. At higher ratios, the signal remains practically constant 
because the maximum number of Luc DNA molecules that can be bound to the immunocomplex 
on the well is achieved. At molar ratios greater than 10, the signal/background ratio (S/B) drops 
sharply. This was attributed to an increase of the non-specific binding of the linker to the solid 
phase. 
 
Fig. 2. Optimization of the molar ratio of (dA)40 to avidin required for the preparation of the linker. 
Linkers were prepared by reacting a constant amount of maleimide-activated avidin with various 
concentrations of the oligonucleotide (dA)40 and then used in the sandwich-type immunoassay of 25 pg 
of PSA as described in Section 2. The solid and dashed lines represent the luminescence and the S/B 
ratio, respectively. 
For the preparation of streptavidin-(dA)40 linkers, maleimide groups were first introduced to streptavidin 
by reacting with SMCC. The reaction was studied at molar ratios of SMCC to streptavidin ranging from 5 
to 100. It was observed that the highest signal and S/B ratio were obtained at a molar ratio of 40. At 
higher SMCC concentrations the signal decreased because of the interference with the biotin–
streptavidin interaction. Optimization experiments of the molar ratio of SMCC-derivatized streptavidin 
to SATA-(dA)40 showed that the maximum signal was obtained at a ratio of 10 (similar to avidin above). 
The effect of the linker concentration used in the immunoassay was studied in the range of 0.4–
80 nmol/l. The results are presented in Fig. 3A. The signal increases with the linker concentration and 
reaches to a plateau at 8 nmol/l. At higher concentrations, the signal remains constant, but the S/B ratio 
decreases due to the increase of the non-specific binding of the linker. 
 
Fig. 3. (A) Effect of linker concentration used in the immunoassay. The signal (solid line) and the S/B ratio 
(dashed line) were plotted as a function of the linker concentration. (B) Time dependence of the binding 
of the linker to the biotinylated anti-PSA antibody. The immunoassays were carried out as described 
in Section 2 with 25 pg of PSA. 
The time required for the binding of the linker to the immunocomplex was studied in the range of 5–
80 min. The results are presented in Fig. 3B. It was observed that 40% of the linker binds to the 
immunocomplex in the first 5 min incubation. A 15 min incubation period generates the highest S/B 
ratio. With longer incubation periods, the S/B ratio drops due to the increased non-specific binding of 
the linker. 
The effect of the poly(dT)-Luc DNA concentration was studied in the range of 0.3–10 nmol/l (Fig. 4A). In 
this study, the linker concentration was kept constant at 8 nmol/l. A continuous increase of the S/B ratio 
is observed with increasing poly(dT)-Luc DNA concentration and a maximum is reached at 1.2 nmol/l. At 
higher concentrations, the S/B ratio decreases because of the increased non-specific binding of Luc DNA. 
 
Fig. 4. (A) Optimization of the concentration of the poly(dT)-Luc DNA in the immunoassay. (B) Time-
dependence of the hybridization of the poly(dT)-tailed reporter gene to the linker. The immunoassay 
was performed as described in Section 2 with 25 pg of PSA. 
We further studied the time required for hybridization of the poly(dT)-Luc DNA to the linker (Fig. 4B). 
Within 5 min, 50% of the Luc DNA is bound to the linker and the highest S/B ratio is obtained after 
15 min incubation. Longer incubation times result in increased non-specific binding of the poly(dT)-Luc 
DNA and lower S/B ratios. 
The calibration curve for a “two-site” (sandwich-type) immunoassay for PSA was constructed by 
analyzing PSA standard solutions. In Fig. 5A, the luminescence was plotted as a function of the PSA 
concentration in the assay mixture. As low as 20 ng/l of PSA were detectable with a S/B ratio of 2.6 and 
the linear range extended up to 20,000 ng/l. The linker was tested further by analyzing (after 
appropriate dilution) 24 serum samples with PSA concentrations ranging from 5 to 50 μg/l by the 
proposed method and another widely used method (Abbott IMx) (Fig. 5B). The linear regression 
equation was (IMx) with a correlation coefficient of 0.98. 
 
Fig. 5. (A) Calibration graph for the proposed immunoassay using the (dA)40-avidin as a linker between 
the detection antibody and the reporter gene. The luminescence (corrected for the background) was 
plotted as a function of the concentration of PSA present in the well. (B) Correlation of PSA 
concentrations obtained by the proposed immunoassay and the IMx method (n=24). 
To assess the reproducibility of the immunoassay, we analyzed serum samples containing 5.4, 15.5 and 
49.9 μg/l PSA. The CVs were 11.8, 9.5 and 5.0%, respectively (n=9). 
The performance of the avidin-(dA)40 and streptavidin-(dA)40 linkers was practically the same. We have 
also prepared an avidin-(dA)25 linker by following the same protocol as described for the 
(dA)40 in Section 2. The luminescence decreased by 25% with the shorter oligonucleotide. 
In addition, we have investigated whether the performance of the linker in the immunoassay would 
benefit by increasing the distance between the oligo(dA) sequence and avidin. A random 17mer oligo 
was derivatized with SATA at the 5′ end and conjugated to avidin as described for (dA)40 in Section 2. 
The linker was then formed by tailing the conjugate (30 pmol) with dATP (3 nmol) using terminal 
transferase (25 units). Therefore, this linker contained a single stranded DNA spacer arm between avidin 
and the poly(dA) tail. Another linker was also prepared with a double-stranded DNA spacer arm 
between avidin and poly(dA) to ensure a more rigid structure for the spacer. A 17 bp double-stranded 
DNA fragment was first prepared by annealing two complementary 17mer oligos, one of them 
containing a NH2 group at the 5′ end. The DNA was derivatized with SATA, conjugated to maleimide-
activated avidin and tailed with dATP. The results obtained with both linkers were practically the same 
as with the original (dA)40 linker. 
The preparation of the reporter gene used in the assay was carried out by simply linearizing the 
appropriate vector with a restriction enzyme (single cutter), preferably one that could create 3′ 
protruding ends, and then tailing with dTTP using terminal transferase. Thus, both ends of the gene are 
tailed simultaneously. The poly(dT)-reporter gene can be used directly in the assay without purification. 
Stability studies showed that the linker does not lose its activity after storage for at least 1 year at −
20 °C. 
The most sensitive assays for proteins are based on the interaction of the analyte with a specific binder 
(antibody, receptor or peptide) that is linked to a signal-generating molecule. In recent years, there is an 
increased research activity on the selection of binders with high affinity and specificity for a large 
number of proteins. Various approaches include recombinant antibodies selected by phage-
display [12] or ribosome-display [13], RNA or DNA aptamers [14], and small organic compounds selected 
through combinatorial library methods [15] and [16]. In most cases, the extent or the position of 
biotinylation of these binders can be optimized to avoid interference with the interaction between the 
binder and the protein. Thus, the proposed (strept)avidin-(dA)40 linker may be used as a universal 
reagent to attach a highly detectable reporter gene to practically any binder molecule targeted to a 
protein analyte. The microtiter well format facilitates automation and high-throughput analysis. 
Enzymes are the most widely used labels in immunoassays. Consequently, efforts toward improving the 
immunoassay detectability have been focused (for decades) on the synthesis of novel substrates. 
Substantial improvements have arisen from the replacement of chromogenic substrates with 
fluorogenic and chemiluminogenic ones. Expression immunoassay, instead of providing an alternative 
means for monitoring enzyme activity, entails an increase in the number of enzyme molecules per 
immunocomplex, thus introducing additional amplification. Furthermore, by using an enzyme-coding 
DNA fragment as a label the problem of enzyme inactivation during conjugation to antibodies is 
eliminated and the enzyme remains free in solution. This is particularly important for firefly luciferase, 
which is inactivated by the chemical reactions involved in direct labeling of antibodies or antigens. 
Moreover, expression immunoassay has shown considerably higher detectability when compared 
directly with fluorescence and chemiluminescence immunoassays and hybridization 
assays [5], [6] and [17]. 
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